{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"LATIFY","nct_id":"NCT05450692","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=latify-nct05450692. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"LATIFY","arms":[{"description":"Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.","label":"Group A: Ceralasertib plus durvalumab combination therapy","type":"EXPERIMENTAL"},{"description":"Participants will be administered docetaxel (standard of care) administered intravenously.","label":"Group B: Docetaxel monotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Parexel"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Advanced or Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":594,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ceralasertib","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-07-13","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-10-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)"}],"references":[],"start_date":{"date":"2022-09-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","url":"https://clinicaltrials.gov/study/NCT05450692"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/latify-nct05450692"}